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pro-atherogenic milieu of uremia. Dialytic therapy, which acts“And so these men of Indostan
to reduce the concentration of oxidized substrates, improvesDisputed loud and long,
the redox balance. However, processes related to dialytic ther-Each in his own opinion
apy, such as the prolonged use of catheters for vascular accessExceeding stiff and strong,
and the use of bioincompatible dialysis membranes, can con-Though each was partly in the right,
tribute to a pro-inflammatory and pro-oxidative state and thusAnd all were in the wrong!”
to a pro-atherogenic state. Anti-oxidative therapeutic strategiesJohn Godfrey Saxe
for patients with uremia are in their very early stages; nonethe-
less, early studies demonstrate the potential for significant effi-
cacy in reducing cardiovascular complications.
The elephant in uremia: Oxidant stress as a unifying concept Cardiovascular disease is the single largest cause ofof cardiovascular disease in uremia. Cardiovascular disease is
mortality in the general population, and as such, it notthe leading cause of mortality in uremic patients. In large cross-
surprising that it is also the leading cause of mortality insectional studies of dialysis patients, traditional cardiovascular
risk factors such as hypertension and hypercholesterolemia chronic dialysis patients. What is surprising and different
have been found to have low predictive power, while markers from the general population is the magnitude of cardio-
of inflammation and malnutrition are highly correlated with vascular complications and the near equivalence of car-
cardiovascular mortality. However, the pathophysiology of the
diac mortality across age groups in uremic patients. Thus,disease process that links uremia, inflammation, and malnutri-
cardiac mortality for dialysis patients aged 45 years ortion with increased cardiovascular complications is not well
understood. We hereby propose the hypothesis that increased younger is more than 100-fold greater than in the general
oxidative stress and its sequalae is a major contributor to in- population. Even in the elderly, cardiovascular mortality
creased atherosclerosis and cardiovascular morbidity and mor- is at least fivefold higher in the end-stage renal disease
tality found in uremia. This hypothesis is based on studies (ESRD) population than in the general population [1].that conclusively demonstrate an increased oxidative burden in
Data are now emerging that strongly suggest that cardio-uremic patients, before and particularly after renal replacement
vascular complications accelerate as renal function is pro-therapies, as evidenced by higher concentrations of multiple
biomarkers of oxidative stress. This hypothesis also provides gressively lost, and that a high percentage of incident
a framework to explain the link that activated phagocytes pro- dialysis patients already have a substantial burden of
vide between oxidative stress and inflammation (from infec- cardiovascular disease as they start their lives on dialysis
tious and non-infections causes) and the synergistic role that
[1, 2]. These findings have led to investigations aboutmalnutrition (as reflected by low concentrations of albumin
specific features of renal insufficiency and loss of kidneyand/or antioxidants) contributes to the increased burden of car-
diovascular disease in uremia. We further propose that retained function that lead to acceleration of atherogenesis.
uremic solutes such as beta-2 microglobulin, advanced glycosy- In the past decade, numerous epidemiologic studies
lated end products (AGE), cysteine, and homocysteine, which have attempted to determine the causative or associated
are substrates for oxidative injury, further contribute to the factors that contribute to the high cardiovascular mortal-
ity in ESRD patients. Such studies have pointed out that
traditional risk factors for cardiovascular mortality inKey words: chronic dialysis, end-stage renal disease, anti-oxidative ther-
apy, mortality and dialysis, proteinuria, hypertension, blood pressure. the general population such as hypertension and hyper-
cholesterolemia do not discriminate well in dialysis pa-Received for publication January 10, 2002
tients [3, 4]. More important than these traditional riskand in revised form March 25, 2002
Accepted for publication April 17, 2002 factors are newer “non-traditional” risk factors that are
seemingly difficult to reconcile. At the risk of oversimpli- 2002 by the International Society of Nephrology
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fying these epidemiologic observations, we chose to sum- (Table 2). First, elevated CRP, a marker of the acute phase
response, is an indirect marker of increased leukocyte ac-marize them as a starting point for a discussion that
attempts to link these seemingly divergent observations tivation and increased oxidant production. Second, mal-
nutrition and more specifically hypoalbuminemia mayto a common and potentially unifying pathophysiological
basis for understanding. contribute to cardiovascular morbidity and mortality by
reducing antioxidant defense, thus resulting in a higher
level of oxidative injury. A third corollary is that renal1. The major causes of mortality in ESRD are cardio-
vascular (50%) and infectious (25%) diseases. replacement therapy, to the extent it can be provided
without inciting further inflammatory and oxidative stim-2. Inflammation, documented by elevated C-reactive
protein (CRP) concentrations as a measure of acute uli, will relieve the uremic state and improve the oxidant-
antioxidant (redox) balance. A final corollary is whenphase response, is associated with increased risk of
cardiovascular mortality. “tissues” have pathologically high concentrations of re-
tained uremic substances such as 2-microglobulin (2m),3. ESRD patients with evidence of protein-calorie mal-
nutrition, documented by lower concentrations of cysteine, and homocysteine, they become substrates for
oxidative actions and subsequent tissue injury, propor-albumin and pre-albumin, have a higher relative risk
of mortality that increases with the extent of hypo- tionate to their concentration. This modification may in-
crease their pathogenicity.albuminemia.
4. Inflammation and malnutrition are interrelated, but The following discussion attempts to elucidate what
is currently known about the extent to which oxidativeeach contributes independently to mortality risk.
5. Aspects of renal replacement therapy that contrib- stress is the “real elephant” in uremia.
ute to inflammation, such as the prolonged use of
catheters for vascular access or the use of bioincom-
THE NATURE OF OXIDATIVE STRESS
patible membranes, are also associated with increased
In 1989 and in the early 1990s, Daniel Steinberg andcardiovascular and infectious mortality risk.
colleagues advanced the hypothesis that the atherogen-6. Hyperhomocysteinemia is highly prevalent in uremia
icity of low-density lipoproteins (LDL) was greatly in-and may be associated with cardiovascular toxicity
creased by oxidative modification (Fig. 2) [5]. Oxida-
tively modified LDL is taken up by scavenger receptors,While much has been learned from these studies of
leading to the conversion of monocytes into foam cells,morbidity and mortality predictors in ESRD patients, it
one of the first steps in the atherosclerotic process. Oxi-also must be recognized that these correlations are largely
dative processes predominantly occur in the mitochon-derived from cross-sectional observations that do not
dria and the mitochondrial cytochrome oxidase enzymeclearly define the pathogenesis of the disease process.
is responsible for 90% of the oxygen humans metabolize.Thus, these observations that provide pieces of a puzzle
This enzyme transfers four electrons to oxygen in a con-without a unifying hypothesis are akin to the story of
certed reaction that produces two molecules of water asthe blind men palpating an elephant, set in a poem by
the product. This complex enzyme contains four redoxJohn Godfrey Saxe. These blind men were asked to tell
centers, each of which stores a single electron. When allof their experiences palpating different parts of an ele-
four redox centers are reduced, the simultaneous transferphant, without seeing the entire animal (Fig. 1). Each
of four electrons to an oxygen molecule takes place withof the blind men was able to palpate one part of the
no detectable intermediate steps, thereby limiting theelephant, and thus was able to describe it in terms that
production of reactive oxygen intermediates. Neverthe-were “partly in the right.” However, because none of
less, a small fraction (1 to 2%) of this reaction doesthem was able to encompass the entire elephant in their
proceed via an intermediate step that results in the for-hands, they were also “in the wrong,” in that they failed
mation of free radicals [6]. In response to this problem,to identify the whole elephant.
mammalian systems have evolved numerous intracellu-The hypothesis we wish to advance for discussion is
lar antioxidant systems including enzyme systems, waterthat the essence of the “elephant” in uremia is the increased
soluble, and fat-soluble free radical scavengers that canoxidative burden in the uremic milieu of patients with
avidly react with and eliminate these intermediate reac-chronic kidney disease. This oxidative burden, leading to
tive oxygen species before they inflict oxidative damageincreased oxidation of protein, lipids and carbohydrates,
to vital cellular components and function.increases as renal disease progresses and is extensive by
While mitochondria are the predominant source ofthe time ESRD develops. The result is an accelerated
“accidental” oxidative stress, phagocytes “deliberately”development of atherogenesis and other manifestations
utilize high levels of oxygen for host defense against patho-of “uremia” such as amyloid bone disease (Table 1).
gens. The respiratory burst of these phagocytes is knownThere are several important corollaries of this hypoth-
esis that may link divergent cross-sectional observations to utilize four enzymes (NADPH oxidase, superoxide
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Fig. 1. The blind men and the elephant. Poem by John Godfrey Saxe (Cartoon originally copyrighted by the authors; G. Renee Guzlas, artist).
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Table 1. The elephant in uremia: A conceptual paradigm
Uremia pathogenesis Additional risk factors Potential mediators Substrates Pathophysiology Pathology
Increased cytokines Acute phase reaction HOCl Cysteine Vascular inflammation Accelerated
Increased complement Malnutrition H2O2 Homocysteine Endothelial injury atherogenesis
activation RRT characteristics Superoxide anion 2m VSMC proliferation and Coronary restenosis
Retained solutes Biocompatibility Peroxynitrite Glucose derivatives migration Accelerated venous
Neutrophil priming Catheter use Hydroxyl radical Proteins: Decreased NO effect intimal hyperplasia
? Fe exposure Carbonyls Vasoconstriction LVH
Infection Thiols Platelet activation 2 amyloidosis
Tyrosine Tissue injury
Lipids:
PUFAs
LDL
Abbreviations are: RRT, renal replacement therapy; HOCl, hypochlorous acid; H2O2, hydrogen peroxide; 2m, ß2 microglobulin; PUFAs, polyunsaturated fatty
acids; LDL, low-density lipoprotein; VSMC, vascular smooth muscle cell; NO, nitric oxide; LVH, left ventricular hypertrophy.
Table 2. Corollaries to the oxidative stress hypothesis light the central role that activated phagocytes and condi-
tions associated with inflammation (and hence phagocyte
activation) play in the increased oxidative burden and
 Elevated CRP is a marker for oxidant production
 Malnutrition and hypoalbuminemia reduce antioxidant defense,
increasing vulnerability to oxidant injury atherosclerosis. Strong association between elevated white Renal replacement therapy relieves the uremic state and improves
blood cell count, and rapid progression of atherosclerosisoxidant-antioxidant balance, provided further inflammatory and
oxidative stimuli are avoided and coronary events have been documented in large
 Retained uremic solutes, such as 2m, homocysteine, and cysteine, population studies [12].may become substrates for oxidative injury, thereby contributing
to tissue injury, proportionate to their concentration Oxidative stress (or oxidant-derived tissue injury) takes
place when the production of oxidants exceeds local anti-Abbreviations are: CRP, C-reactive protein; 2m, 2 microglobulin.
oxidant capacity. When this occurs, it results in the oxida-
tion of important macromolecules, including proteins,
lipids, carbohydrates, and DNA present in that environ-
dismutase, nitric oxide synthase, and myeloperoxidase) ment. Because the active oxygen intermediates are pro-
to produce the reactive intermediates superoxide anion, duced in vivo in minute quantities and are also highly
hydrogen peroxide, nitric oxide, and hypochlorous acid reactive, direct in vivo detection of the unreacted moities
(HOCl), respectively, for the destruction of invading mi- is extremely difficult. Nonetheless, a powerful strategy has
croorganisms (Fig. 3). More recently, an additional novel evolved for understanding the underlying in vivo mecha-
oxidative pathway has been identified whereby phago- nisms of oxidative injury by identifying stable end-prod-
cytes convert nitrite to nitryl chloride and nitrogen diox- ucts of oxidation produced by different reaction path-
ide via the myeloperoxidase enzyme or by HOCl itself,
ways. These biomarkers of oxidative pathways increasingly
resulting in nitration of target biomolecules [7].
have been used as an in vivo tool to elucidate the impor-While each of these phagocyte-derived oxidants can
tance of oxidative stress as a contributor to many diseasecontribute to tissue injury, recent studies have empha-
states, including uremia [13, 14]. Table 3 lists the bio-sized the importance of myeloperoxidase-catalyzed chlo-
chemistry of some of the most important of in vivo bio-rinating oxidative reactions. Myeloperoxidase (MPO) is
markers that have been specifically identified at highone of the most abundant proteins in phagocytes, consti-
concentrations in uremia. Figure 4 describes the biochem-tuting approximately 5% of neutrophil protein and 1%
istry of some of the more recent important biomarkerof monocyte protein. MPO is rapidly secreted upon stim-
assays of oxidant stress, which are summarized below.ulation and catalyzes the oxidation of halides to their
corresponding hypohalous (for example, hypochlorous)
acids in the presence of hydrogen peroxide [8]. Quanti- BIOMARKERS OF OXIDATION
tative studies have revealed that H2O2 generated by ac- Lipid peroxidationtivated neutrophils is virtually stochiometrically con-
Several groups of investigators have now used highlyverted to HOCl. Histological analysis of atherosclerotic
sensitive and specific assays to conclusively demonstratetissue have identified catalytically active myeloperoxi-
that there are higher levels of plasma lipid oxidation indase co-localized with foamy macrophages, [9] and both
uremic patients compared to healthy subjects. For exam-3-chlorotyrosine and dityrosine, which are MPO-catalyzed
ple, arachidonic acid has been shown to undergo non-end-products of tyrosine oxidation, have been found in
enzymatic, free radical-induced, peroxidation reactionsoxidatively modified LDL and in human atherosclerotic
lesions [10, 11]. These phagocyte driven reactions high- resulting in the formation of a series of prostaglandin
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Fig. 2. Potential mechanisms for the role of
oxidatively-modified low-density lipoprotein
(LDL) in atherogenesis. Endothelial cells, vas-
cular smooth muscle cells, or macrophages may
catalyze the oxidative modification of circulat-
ing LDL leading to: (I ) recruitment of circu-
lating monocytes; (II ) macrophage “trapping”
in the vessel intima; (III ) enhanced uptake of
oxidized LDL by resident macrophages lead-
ing to foam cell formation; and (IV ) endothe-
lial cell destruction as a result of oxidized LDL
toxicity (reprinted with permission from Quinn
MT et al, Proc Natl Acad Sci USA, 82:5949–
5953, 1985).
Table 3. In vivo oxidative stress biomarkers
useful in evaluating uremia
Lipids
Malondialdehyde and other aldehydes
Lipid hydroperoxides
Oxidized low-density lipoprotein (LDL)
Exhaled alkanes
Advanced lipoxidation end products (ALE)
Arachidonic acid derivatives
F2 isoprostanes
Isolevuglandins
Carbohydrates
Reactive aldehydes
Advanced glycosylation end products (AGE)
Amino acids
Cysteine/cystine
Homocysteine/homocystine
Fig. 3. Pathways of oxidant generation by activated leukocytes. Isoaspartate
3-chlorotyrosine
Dityrosine
3 nitrotyrosine
ProteinsF2-like compounds known as F2 isoprostanes (F2-IsoPs; Thiol oxidation
Fig. 4B) [15]. F2-IsoPs are initially formed in situ on Carbonyl formation
Advanced oxidation protein products (AOPP)phospholipids and then subsequently can be released in
DNAthe plasma and, therefore, they can be detected either 8 hydroxy 2 deoxyguanine
as free or as phospholipid-bound F2 isoprostanes. Levels Other
Spin traps (electron paramagnetic resonance)of F2-IsoPs in human biologic fluids exceed cyclooxygen-
ase-derived prostanoids by greater than an order of mag-
nitude and are a reliable indicator of oxidative stress in
vivo. Recent findings have shown that plasma F2 isopros-
to plasma proteins because of their extreme reactivity.tane levels are two to four times higher in patients re-
Salomon et al have recently demonstrated that patientsceiving chronic hemodialysis therapy as in age- and sex-
with ESRD receiving hemodialysis have approximatelymatched controls and correlate closely with levels of
twice the level of isolevuglandin-plasma protein adductsC-reactive proteins [16, 17].
as healthy subjects [18]. Handelman et al also demon-Another family of extremely reactive electrophiles,
strated that levels of breath ethane (which result from theknown as isolevuglandins, is generated in vivo by free rad-
beta scission of lipid hydroperoxides) are approximatelyical-induced lipid oxidation of arachidonic acid. In con-
fourfold in hemodialysis patients compared to healthytrast to F2 isoprostanes, isolevuglandins do not circulate
free in the plasma, but are virtually completely adducted subjects (abstract: Handelman et al, J Am Soc Nephrol
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Fig. 4. Biochemistry of oxidant stress biomarkers. (A) Oxidation of tyrosine residues. (B) F2-isoprostane generation from arachidonic acid via
free radicals. (C ) Generation of reactive aldehydes (carbonyls). (D) Amino acid thiol group oxidation. (E ) DNA oxidation. Abbreviations are:
HOCL, hypochlorous acid; MPO, myeloperoxidase; CML, carboxymethyllysine; HNE, hydroxynonenal.
11:271A, 2000). Thus, a variety of highly sensitive and (HNE), a product of lipid oxidation, with lysine residues
[19]. Salomon et al, using an ELISA assay with antibod-specific assay systems all demonstrate that biomarkers
of lipid peroxidation are higher in dialysis patients than ies raised against protein bound 2-pentylpyrrole, have
demonstrated markedly elevated HNE-derived 2-pen-in healthy subjects.
Several investigators also have re-examined the issue tylpyrrole levels in LDL in patients on both hemo- and
peritoneal dialysis compared to healthy subjects [20].of whether plasma LDL is more oxidized in patients with
uremia compared to healthy subjects, using more sensi- Using different techniques, Ziouzenkova et al measured
the amino group oxidation in APO B100 protein to de-tive and specific assays than in the past. Free plasma
LDL produces detectable 2-pentylpyrrole epitopes that tect minimal oxidative modifications in LDL [21]. They
demonstrated that minimally oxidatively modified LDLare generated by the reaction of 4-hydroxy-2-nonenal
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levels (which are associated with atherosclerosis) are
higher in hemodialysis patients compared to healthy sub-
jects, suggesting that this may be free radical-mediated
by the interaction of dityrosine with LDL-associated pro-
tein. Taken together, these studies provide compelling
evidence that increased free radical-mediated oxidative
processes lead to increased lipid, apolipoprotein, and
lipoprotein oxidation in patients with ESRD receiving
dialysis therapy.
Protein and amino acid oxidation
Oxidatively modified plasma proteins and amino acids
also can serve as important in vivo biomarkers of oxida- Fig. 5. Elevated plasma protein 3-chlorotyrosine, a specific biomarker
of myeloperoxidase-catalyzed oxidation, in hemodialysis patients.tive stress. The ready accessibility of plasma proteins
(Adapted with permission from Himmelfarb et al, Free Radical Biol-and amino acids for sampling, the relatively long plasma
ogy & Medicine 31:1163–1169, 2001.)
half-lives of many proteins, and the well-defined bio-
chemical pathways that lead to protein and amino acid
oxidation can be used to detect more specific pathways
of oxidative stress than plasma lipids. For example, oxi- oxidative protein products (AOPP) in the plasma of ure-
dation of amino acyl side chains of amino acids in pro- mic patients [26–28]. These investigators also demon-
teins is an attractive biomarker of oxidative reactions strated that hypochlorous acid derived from activated
because of the high specificity of the end products for spe- phagocytes in vitro could replicate the production of
cific oxidation pathways. Detection of tyrosine residue plasma AOPP to levels seen in uremic patients [28]. Fi-
oxidation currently constitutes the most sensitive and nally, l-isoaspartyl residues in plasma proteins from
specific means available for detecting end products of uremic patients are also increased as a manifestation of
specific oxidative pathways (Fig. 4A) [22]. In particular, oxidative injury [29]. Collectively, these studies using
oxidation of tyrosine residues leads to the formation of protein and amino acids as biomarkers strongly suggest
3-chlorotyrosine, 3-nitrotyrosine, or dityrosine, depend- that myeloperoxidase-catalyzed hypochlorous acid de-
ing on whether the predominant oxidizing species is hy- rived from activated phagocytes is an important oxidant
pochlorous acid, a reactive nitrogen species, or a free in uremic patients.
radical (such as hydroxyl ion), respectively [22]. Our The previous discussion has served to highlight the
group has recently demonstrated that plasma proteins
specific pathways of oxidative stress and their perva-
from hemodialysis patients contain elevated levels of
siveness in uremia. In order to highlight the clinical im-3-chlorotyrosine, but not 3-nitrotyrosine or dityrosine
portance of these oxidation by-products, it is important(Fig. 5). Since this product (3-chlorotyrosine) is a specific
to link these pathways to specific and common diseaseproduct of myeloperoxidase catalyzed reaction, it further
manifestations in patients with uremia. For the sake ofsuggests a specific and important role for phagocyte-
brevity, we will attempt to demonstrate the clinical rele-initiated oxidative reactions as the cause of excess oxida-
vance of two specific pathways: one related to the forma-tive stress in uremia [23].
tion and accumulation of aldehydes and one to the deple-In addition to oxidized tyrosine residues, other impor-
tion of reduced thiols.tant amino acyl groups subject to oxidation include sulfur
groups (cysteine, methionine), amino groups (such as ly-
sine), and alcohol groups (including threonine). Recent UREMIA, OXIDATIVE STRESS, AND
studies from our group and other investigators have clearly ALDEHYDE FORMATION
demonstrated high levels of thiol group oxidation as well
Reactive aldehydes can be formed as the end productas carbonyl formation in plasma proteins from patients
of a variety of oxidative reactions including oxidation ofwith uremia (Fig. 6) [24]. While not entirely specific for
alcohol groups, amino groups, and via the addition ofa single oxidative pathway, levels of plasma protein oxi-
oxygen to unsaturated carbon double bonds in carbohy-dation and carbonyl formation seen in uremic patients
drates, lipids, or amino acids (Fig. 4C) [30]. Biochemicalin vivo are similar to patterns of protein thiol oxidation
assays designed to detect accumulation of aldehydes relyobserved in vitro after oxidation with hypochlorous acid,
on identification of carbonyl (C  O) groups, leading tobut not with hydrogen peroxide, again suggesting an im-
the use of the term “carbonyl stress.” Myeloperoxidase-portant role for myeloperoxidase in generating oxidant
catalyzed oxidative modification of amino acids also canstress [24, 25]. A series of studies by Witko-Sarsat and col-
leagues have demonstrated elevated levels of advanced lead to the formation of a variety of reactive aldehyde
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sclerosis [30, 35]. AGEs may promote atherosclerosis
through interactions with specific receptors (RAGE),
causing increased expression of adhesion molecules and
enhanced attraction of circulating monocytes to the ves-
sel wall. It is important to note that the interaction of
AGE with its RAGE receptor also leads to the increased
production of interleukin-6 (IL-6) by monocytes and in-
directly to the excess formation by CRP in the liver, thus
participating in the genesis of inflammation.
Reactive aldehydes have been shown to be involved
in the oxidative modification of LDL cholesterol, both
in vitro and in vivo, thereby making this modified LDL
a target for monocyte phagocytosis and the development
of foam cells, a precursor of the atherosclerotic process
[36]. The participation of reactive aldehydes in the ath-
erosclerotic process also is suggested by immunohisto-
chemical analyses of atherosclerotic lesions from human
aorta, in which intense positivity of a variety of aldehyde
adducts including HNE-histadine, MDA lysine, and
acrolein-lysine, can be demonstrated in association with
macrophages and foam cells [37].
In summary, carbonyl concentration as an index of
reactive aldehyde formation represents the end product
of oxidative and other pathways. Carbonyl concentra-
tion is important both in the pathogenesis of atheroscle-
rosis in uremia and as a potential biomarker to monitor
antioxidative therapeutic strategies. To the extent that
carbonyl formation is a byproduct of phagocyte-derived
Fig. 6. Plasma protein thiol group oxidation (A) and carbonyl forma- myeloperoxidase reactions, carbonyl concentration is alsotion (B) in patients with chronic kidney disease and hemodialysis pa-
a marker of phagocyte activation and the inflammatorytients, demonstrating that plasma protein oxidation develops in renal
disease well before ESRD. (Adapted with permission from Himmelfarb burden.
et al, Kidney Int 58:2571–2578, 2000.)
UREMIA, OXIDATIVE STRESS, AND
DEPLETION OF REDUCED THIOLcompounds including glyoxal, methylglyoxal, acrolein,
In addition to the generalized metabolic disturbanceglycoaldehyde, and parahydroxy phenacetaldehyde [31].
in uremia resulting in excess accumulation of reactiveSeveral groups have demonstrated that reactive car-
aldehydes, it is becoming increasingly clear that there isbonyl compounds can be detected in uremia in concen-
a concomitant depletion of reduced thiol groups. Thiolstrations far in excess of normal healthy subjects [24, 25,
are a class of organic sulfur derivatives that are character-31–33]. Assays measuring total reactive carbonyl com-
ized by the presence of sulfhydryl residues at their activepounds (by measuring hydrazone formation after reac-
site. Thiols have critical intracellular and extracellulartion with 2,4-dinitrophenylhydrazine) have shown that
function as redox buffers, via protein thiol (S-H)/disul-total carbonyl compounds are found at a concentration
fide (S-S) concentration equilibrium (Fig. 4D) [38]. Be-up to tenfold higher in uremic plasma compared to nor-
cause the formation and cessation of disulfide bonds aremal plasma [24, 31].
involved in many enzymatic and transport processes, thiolThe significance of elevated concentrations of alde-
oxidation has significant effects on protein structure andhydes, measured as reactive carbonyl compounds in ure-
function [39]. For example, intracellular thiols such asmia is most clearly demonstrated by their role in the for-
glutathione and thioredoxin play an important role inmation of advanced glycosylation end products (AGEs).
maintaining the highly reduced environment inside theAGEs are formed nonenzymatically by irreversible reac-
cell [38]. Extracellular thiols also constitute an importanttion of reactive carbonyl compounds with various amine
component in antioxidant defense relevant to cardiovascu-groups in proteins [34].
lar disease [40–46]. The extracellular fluids of the humanThe importance of increased reactive aldehyde and
body, including plasma, contain little or no catalase activ-AGE formation is evidenced by their prominent role in
the pathogenesis of vascular diseases including athero- ity and only low levels of common antioxidants such as
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superoxide dismutase, glutathione and selenium-contain- INFLAMMATION AND OXIDATIVE STRESS
ing glutathione peroxidase [47]. Thus, traditional anti- Inflammation is a common feature of ESRD and it
oxidant enzymes that are crucial in intracellular defense has been recognized that about 30 to 50% of predialysis,
are unavailable and play a minimal role in protection hemodialysis (HD), and peritoneal dialysis (PD) patients
against oxidative injury in extracellular fluids. Halliwell have serologic evidence of an activated inflammatory
and others have demonstrated that the protein-associ- response [54]. Ward and McLeish have reported that
ated thiols and ascorbate constitute the major extra- phagocyte cells that are “primed” in uremia may contrib-
cellular defense against oxidant stress in plasma [47–49]. ute to increased production of both reactive oxygen spe-
The importance of plasma protein-associated free thiols cies as well as cytokines [55]. An elevation of plasma
in scavenging both free radicals and myeloperoxidase- CRP is one indication of a cytokine-driven (especially
IL-6) acute phase inflammatory response. The clinicalgenerated oxidants has been demonstrated in several
significance of CRP in dialysis patients has been wellstudies [50].
documented in a series of recent studies in which anGiven the importance of the antioxidant actions of
elevated CRP has been shown to be a strong predictorthiols both intracellularly and particularly extracellularly,
of adverse clinical outcomes and increased cardiovas-it is instructive to examine the relative concentrations of
cular mortality [reviewed in Arici and Walls, 56]. Thereduced and oxidized thiols in uremia. Ceballos-Picot et
interaction of AGE with its RAGE receptor leading toal investigated the glutathione antioxidant system in the
increased production of IL-6 and CRP also was pre-plasma of a large cohort of patients with chronic renal
viously discussed [56]. Finally, the highly skewed distri-failure and demonstrated diminished plasma glutathione
bution of CRP and IL-6 elevations in dialysis patientslevels and a profound drop in glutathione peroxidase func-
and the episodic nature of CRP increases suggest thattion [51]. Our group has demonstrated that plasma pro-
patient-specific processes (such as clotted access grafts,tein thiols are extensively oxidized in uremic patients
dialysis membrane bioincompatibility, or persistent clini-compared to healthy subjects [24]. We and others also
cal or sub-clinical infections) may be important causeshave examined the redox status of the low molecular
of chronic inflammation in ESRD patients.weight amino thiols cysteine, homocysteine, and cys-
Although the association between atherosclerosis andteinyl-glycine, which are well-known accumulate in ure-
chronic inflammation in the dialysis patient popula-mia [52, 53]. In each of these aminothiols, the ratio of
tion is well documented, we do not know if the inflam-oxidized to reduced thiols is considerably increased in
matory response merely reflects an epiphenomenon ac-hemodialysis patients compared to healthy subjects [53].
companying established atherosclerotic disease or whetherThus, these studies demonstrate a generalized increase
inflammation and various acute-phase reactants are in-in thiol oxidation and a concomitant decrease in both
volved in the initiation and/or progression of athero-
protein-associated and low molecular weight reduced
sclerosis. Clearly, systemic infection and other causes of
plasma thiols, which are quantitatively the major redox
chronic inflammation may contribute directly to mortal-
change in uremic plasma. ity independent of the atherosclerotic process. Nonethe-
It should be noted that the increase in reactive alde- less, data are beginning to emerge linking inflammation
hyde formation and decrease in reduced thiol, which are (as manifested by an increase in CRP) and oxidative stress
concomitantly present in uremia, might be interrelated in dialysis patients. Nguyen-Khoa et al recently demon-
and synergistic in their biologic effects. Reactive al- strated a positive correlation between elevated plasma
dehyde groups preferentially bind to thiols, which can CRP levels and plasma thiobarbituric acid reaction sub-
thereby function to detoxify or scavenge reactive alde- stance (TBARS) as a measure of lipid peroxidation in
hydes. Thus, the presence of depleted thiols in the setting chronic hemodialysis patients [57]. These investigators
of increased reactive aldehyde production in uremia may additionally demonstrated a negative correlation between
synergistically tip the redox balance in favor of increased plasma CRP levels and plasma alpha tocopherol levels,
injury from oxidative stress. consistent with the hypothesis that inflammation depletes
In summary, recent evidence accumulated by multiple antioxidants. Elevated plasma F2 isoprostane levels in the
investigators incontrovertibly demonstrate that the ure- hemodialysis patient population are positively correlated
mic milieu is a milieu of increased oxidant stress, affect- also with CRP, a finding our group has corroborated
ing lipid, carbohydrate, protein, amino acid, and DNA [16, 17]. These observations suggest an important patho-
structure. With this background, we now wish to examine physiologic link between markers of inflammation and
the important and somewhat more speculative relation- biomarkers of oxidant stress in dialysis patients. How-
ships between increased oxidative stress and inflamma- ever, more research is required to firmly establish the path-
tion, malnutrition, renal replacement therapy, and solute ophysiologic relationships between inflammation and
oxidant stress in uremia, and to determine if oxidantretention in patients with uremia.
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injury is the direct mediator of accelerated cardiovascu-
lar complications observed in dialysis patients with ele-
vated markers of acute phase reactants.
MALNUTRITION AND OXIDATIVE STRESS:
ROLE OF HYPOALBUMINEMIA
Oxidative injury generally takes place only when local
oxidant production exceeds antioxidant defense. As dis-
cussed previously, the intracellular milieu is maintained
in a highly reduced state, and cells have evolved complex
enzymatic defense against oxidant injury. In contrast, ex-
tracellular fluids generally contain much lower concen-
trations of similar antioxidants [47]. In plasma, the most
important antioxidant is provided by thiol groups, which
are largely located on the albumin molecule. The concen-
tration of these thiol moieties has been estimated to be Fig. 7. The malnutrition inflammation syndrome tips the redox balance
toward oxidative stress and cardiovascular disease.as high as 500 mol/L. These thiol moieties act as scav-
engers of hypochlorous acid and other oxidants [58].
While ascorbate is also an important extracellular anti-
gistic effect on the risk for cardiovascular toxicity, since
oxidant, albumin, via its thiol groups, provides quantita-
inflammation would result in increased production of oxi-
tively almost tenfold greater antioxidant protection [49].
dants by leukocytes and hypoalbuminemia results in re-
The albumin molecule has been demonstrated to inhibit
duced scavenging capacity for these oxidants (Fig. 7). Us-
copper ion-dependent generation of hydroxyl radicals
ing plasmalogen as an index of oxidative stress, our group
and lipid peroxidation. In other studies, in addition to
has demonstrated that malnourished patients with ad-
its active antioxidant moieties, albumin has been shown
vanced chronic kidney disease have increased oxidative
to be selectively oxidized by a variety of oxidants, thereby stress compared to well-nourished patients [66].
functioning as a “suicide scavenger” preventing oxida- When hypoalbuminemia arises, in part or in whole,
tive injury to both lipoproteins and the vascular wall because of poor nutritional intake, low albumin concen-
[47, 58]. Our group has recently demonstrated that oxida- tration may be a surrogate for the lowered concentration
tion of free thiol groups on plasma albumin is one of of other important antioxidants as well. For example,
the hallmarks of uremic oxidant stress, quantitatively the major source of reducing equivalents to maintain
accounting for most of the measurable oxidation-induced intracellular redox health comes from nutrients that are
alterations in plasma [24]. Another recent study from substrates for the pentose phosphate pathway. It is
our group also demonstrated that albumin is the major tempting to speculate that circumstances associated with
plasma protein target for carbonyl formation in patients hypoalbuminemia resulting from decreased dietary pro-
with uremia [59]. Albumin can act as a binding protein tein intake also are associated with caloric deprivation,
for products of oxidation of carbohydrates, lipids, and thereby diminishing the activity of the pentose phos-
proteins. As an example, AGEs such as pentosidine and phate pathway and the ability to maintain the intracellu-
carboxymethyllysine are more than 90% albumin-bound lar milieu in a highly reduced state. Similarly, when hypo-
when circulating in the plasma [60, 61]. albuminemia occurs due to diminished nutritional intake,
These observations provide the framework for a path- because of either illness or anorexia, the burden of oxida-
ophysiologic link between the clinical observations in tive injury may be increased by diminished intake of
cross-sectional studies that hypoalbuminemia correlates exogenous antioxidants such as ascorbate and tocopher-
with cardiovascular mortality in ESRD patients [62–64]. ols. Ascorbate in particular is dialyzed through most
According to this hypothesis, patients with malnutrition high-flux dialysis membranes, and its concentration in
and a low plasma albumin concentration will have a dialysis patients is significantly lower.
significantly diminished plasma antioxidant capacity due
to the diminished availability of thiol groups. A direct
RETAINED UREMIC SOLUTES MAY BECOMEcorrelation between antioxidant capacity of plasma and
SUBSTRATES FOR OXIDATIVE INJURYserum albumin concentrations in patients with nephrotic
syndrome supports this hypothesis [65]. The oxidative As renal failure progresses, compounds begin to accu-
stress hypothesis of vascular injury also suggests that the mulate in uremic blood and tissues directly or indirectly
combination of increased inflammation (as manifested by due to declining renal clearance. Vanholder et al recently
pointed to a number of retention solutes that may con-elevated CRP) and hypoalbuminemia will have a syner-
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tribute to vascular damage in uremia, including comple- Hyperhomocysteinemia in renal failure has been postu-
lated to contribute to atherosclerosis development, al-ment peptides, cytokines, phosphate, oxalate, and di-
methyl arginine [67]. Vanholder et al suggested that urea, though at present, the pathogenetic linkage between
hyperhomocysteinemia and the development of athero-oxalic acid, parathyroid hormone, and 2 strictly meet
the criteria of uremic toxins. These uremic retention sol- sclerosis is controversial in this patient population [re-
viewed in 76].utes lead to a deterioration in biochemical and physio-
logic function, resulting in the uremic syndrome [68]. In In addition to being present in the plasma in higher
quantities, both homocysteine and cysteine are morethe past decade, a number of additional solutes including
homocysteine, indoles, and para-cresol also have been oxidized in uremic patients than healthy subjects. Similar
to 2m, the extent of homocysteine and cysteine oxida-suggested to function as uremic toxins.
As our understanding of uremic toxicity grows, it is tion is correlated with their respective plasma concentra-
tions in the uremic patient population [53]. These find-becoming increasingly clear that many retained uremic
solutes can become substrates for further biochemical ings suggest that homocysteine and cysteine function
as uremic retention solutes that are further subject tomodification in the uremic milieu and may thus further
contribute to toxicity. Indeed, there is evidence to sug- oxidative modification by the uremic environment. In
vitro studies have shown that cystine, the oxidized formgest that they may be toxic only after oxidative modifica-
tion. For example, while urea may or may not be directly of cysteine, activates vascular smooth muscle cells to
further produce reactive oxygen species such as superox-toxic [69], many molecules can be carbamylated in the
presence of sustained high concentrations of urea. Car- ide [79]. Thus, the oxidation or auto-oxidation of these
uremic solutes may contribute to vascular wall toxicitybamylated LDL is another modification of LDL that
can be taken up by scavenger receptors on monocytes, and may further increase their atherogenicity.
While these findings are provocative, it must be recog-thereby initiating the atherosclerotic plaque and contrib-
uting to the pathogenesis of atherosclerosis [70]. nized that our understanding of the uremic syndrome
Several lines of evidence are beginning to suggest that on a biochemical level, although progressing, is still in
oxidative modification of retained uremic solutes may its infancy. The interactions between retained uremic
potentiate their pathogenicity. It is now well known that solutes and further biochemical modifications in the ure-
2m amyloidosis is a serious complication that occurs in mic milieu that contribute to increased toxicity is an
the majority of patients undergoing long-term hemodial- emerging concept and more research in this area will
ysis [71]. While the pathogenesis of 2m amyloidosis is likely develop in the future.
still not completely understood, recent studies have em-
phasized that in addition to substrate retention, biochem-
RENAL REPLACEMENT THERAPYical modification of the 2m molecule in the uremic milieu IMPROVES REDOX BALANCEcontributes to its pathogenicity. For example, an isoform
If the uremic milieu is characterized by an alterationof the 2m molecule with a more acidic isoelectric point
in redox chemistry favoring oxidant-mediated injury, itis now recognized as a component of amyloid deposits
is logical to assume that amelioration of the uremic statefrom patients undergoing dialysis [72, 73]. Acidification
by renal replacement therapy would correspondingly im-of the 2m molecule is due to progressive glycation and
prove the redox balance toward the normal state. Thisoxidation through the non-enzymatic Maillard reaction
issue has recently been investigated by examining the re-[74]. The resulting AGE-modified 2m can bind to AGE
dox state of plasma thiols, an important marker of plasmareceptors (RAGE) on monocytes leading to monocyte
antioxidant capacity, before and after the hemodialysisactivation, cytokine production, and further reactive ox-
procedure in patients with chronic renal failure [24, 53].ygen species formation [75]. Monocyte infiltration is now
In an initial study, our group demonstrated that plasmarecognized as an important component of the tissue de-
protein thiol groups are markedly oxidized prior to thestruction that occurs in 2m amyloidosis. Our group has
dialysis procedure but are restored to the levels seen inshown that polymerization of 2m is greatly facilitated
healthy subjects by the end of the dialysis procedurein the presence of an oxidative stress, reproduced in vitro
[24]. In a subsequent investigation, we demonstrated thatby complement-activated neutrophils.
each of the major plasma amino thiols (cysteine, homo-Our recent work suggested that homocysteine and cys-
cysteine, cysteinyl-glycine, and glutathione) is more oxi-teine also function as retained uremic solutes that be-
dized in uremic patients prior to the hemodialysis proce-come substrates for oxidative modification [53]. Both
dure than in healthy subjects. For each of these fourhomocysteine and cysteine plasma levels are elevated
plasma amino thiols (which collectively constitute anseveral-fold in uremic patients compared to healthy sub-
important extracellular redox buffering system), redoxjects [44, 52, 53, 76, 77]. Epidemiologic studies have cor-
status improved toward the level seen in healthy subjectsrelated hyperhomocysteinemia and hypercysteinemia with
atherosclerotic disease in the general population [78]. by the end of the dialysis procedure [53]. These results
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strongly suggest that a major beneficial effect of the genic properties and may result in oxalate accumulation
[86]. Furthermore, vitamin C can contribute to the libera-hemodialysis procedure is to restore redox balance to-
ward normal. In other words, alleviation of the uremic tion of ferrous iron from stored iron, which may be a
particular problem in intravenous iron-treated patientsstate exceeds the potential pro-inflammatory effects of
the dialysis procedure itself in improving redox balance. [87]. The reducing potential of vitamin C potentially
leads to the metal catalyzed production of hydroxyl radi-Support for this concept also comes from earlier work
by Roselaar et al, who demonstrated the presence of a cals with deleterious consequences [87]. In the absence of
overt ascorbate deficiency, risks and benefits of ascorbatestable low molecular weight dialyzable oxidant in the
plasma of chronic hemodialysis patients using electron administration in the uremic population will have to be
weighed carefully.spin resonance spectroscopy [80]. These investigators
also demonstrated a redox improvement toward normal The administration of alpha tocopherol (vitamin E) is
a much more promising strategy to alleviate oxidativefrom pre- to post-dialysis. Our group demonstrated that
twelve months of dialysis treatment improves plasmalo- complications in uremic patients. Studies to date have
reported conflicting results as to whether vitamin E levelsgen levels (a marker of oxidative stress) toward levels
seen in healthy subjects [66]. are low, normal, or even high in uremic patients com-
pared to healthy subjects. However, the administrationHowever, since it is well established that extracorpo-
real dialytic therapies can lead to complement activation, of alpha tocopherol to uremic patients almost universally
has been associated with improvements in biochemicalleukocyte activation, and other pro-inflammatory changes
[81], it is also conceivable that the dialysis procedure measures of oxidant stress and interestingly has frequently
been associated with improvements in the anemia ofitself can lead to pro-inflammatory and pro-oxidative
changes. Thus, for example, it is well known that dialy- chronic renal disease, likely as a result of decreased oxi-
dant-mediated erythrocyte destruction (Table 4).sis using unmodified cellulosic (bioincompatible) mem-
branes vigorously activate the alternative pathway of Recently, Boaz et al published the results of an impor-
tant study (Secondary Prevention with Antioxidants ofcomplement and lead to both neutrophil and monocyte
activation, with increased production of cytokines and Cardiovascular Disease in End Stage Renal Disease –
SPACE) in which 196 patients on chronic hemodialysisoxidants [81]. While it is noteworthy that our group and
others have not been able to demonstrate an increase therapy were randomized to receive either placebo or
800 IU of alpha-tocopherol daily, with a median follow-in either protein-associated 3-chlorotyrosine or plasma
F2 isoprostane content (biomarkers of different oxidative up of 519 days [88]. This study demonstrated a substantial
reduction in myocardial infarction and other cardiovas-pathways) during a single dialysis session with cellulosic
membranes, it is also true that the long-term repetitive cular events in the vitamin E-treated group compared
to patients receiving placebo (Fig. 8). However, despiteuse of bioincompatible membranes has been associated
with worsening nutritional status [82, 83], increased car- the marked improvement in cardiovascular morbidity,
there was no difference in overall survival between thediovascular and infectious mortality [84], and an increase
in 2m amyloidosis and higher CRP levels. Given these two treatment groups, suggesting the need to investigate
additional strategies to improve overall survival. Further,countervailing proclivities, it is difficult to predict a priori
what the effect of the dialysis procedure will be on the studies of vitamin E administration for secondary cardio-
vascular prevention in non-uremic patients have gener-redox balance in uremic patients. However, pro-inflam-
matory processes such as the use of bioincompatible mem- ally not been found to be beneficial [89].
branes or catheters should be avoided whenever possible
in order to favor the restoration of the anti-oxidant po- WHITHER THE ELEPHANT?
tential of dialysis.
In the foregoing, we have attempted to provide mul-
tiple lines of evidence that increased oxidative stress,
EVIDENCE FROM CLINICAL TRIALS primarily (but not exclusively) resulting from activated
phagocytes via the myeloperoxidase pathway, leads toThe emerging evidence linking uremia to an increase
in oxidative stress and cardiovascular injury will of neces- oxidation of several types of macromolecules in uremia.
The consequences of excess oxidation include lipid andsity lead to new therapeutic approaches designed to ame-
liorate the devastating consequences of vascular disease LDL peroxidation, excess oxidation of atherogenic thiols
such as homocysteine and cysteine, excess generation ofin this patient population. Logical candidates for therapy
include free radical chain-breaking antioxidants such as atherogenic reactive carbonyl groups, and depletion of
important plasma antioxidants. The sequela of this pro-vitamin C and vitamin E. Caution must be exercised,
however, in considering the administration of large doses cess includes, among others, accelerated development of
the atherosclerotic plaque. We also attempted to provideof vitamin C, as vitamin C can function as both an antioxi-
dant and a pro-oxidant [85], and may have procarcino- a pathophysiologic link between inflammation, malnu-
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Table 4. Effect of alpha-tocopherol (vitamin E) in dialysis patients
Duration N
Study Dose days uremic patients Effect
Giardini et al [91]
Clin Nephrol, 1984 300 mg IM 15 19 Increased Hct
Ono et al [92]
Nephron, 1985 600 mg 30 30 Increased Hct
Yukawa et al [93]
Nephrol Dial Transplant, 1985 600 mg 14 5 Improved MDA-LDL metabolism
Lubrano et al [94]
Artif Organs, 1986 300 mg IM 15 10 Decreased PBMC MDA
Lubrano et al [95] Decreased RBC, MDA
Nutrition, 1992 300 mg IM 15 9 Decreased hemolysis
Sanaka et al [96] No treatment effects on
Clin Nephrol, 1995 500 mg 11 9 phospholipid hydroperoxidase
Cristol et al [97]
Nephrol Dial Transplant, 1997 500 mg 180 7 Reduced EPO dose
Roob et al [98] Attenuate iron-induced lipid
J Am Soc Nephrol, 2000 800 IU 1 22 peroxidation
Islam et al [99] Prolonged lag phase LDL
Atherosclerosis, 2000 800 IU 84 33 oxidation
Boaz et al [88] Decreased MI
Lancet, 2000 800 IU 519 97 Decreased CV event
Abbreviations are: Hct, hematocrit; LDL, low-density lipoprotein; PBMC, peripheral blood mononuclear cells; MDA, malodialdehyde; RBC, red blood cells;
EPO, erythropoietin; MI, myocardial infarction; CV, cardiovascular.
process, which hopefully will lead to the way to larger,
more comprehensive clinical trials.
The SPACE trial may be analogous to early studies
examining the hypothesis that lowering serum choles-
terol levels could reduce cardiovascular morbidity and
mortality. In studies by the Lipid Research Clinics and
other groups, utilizing lipid-lowering agents that by to-
day’s standards would be considered relatively ineffec-
tive, cardiovascular morbidity was lowered without a cor-
responding improvement in cardiovascular mortality [90].
Only with the development of combination anti-lipi-
demic therapy, and then subsequently with the develop-
ment of statins, was a profound reduction in cardiovascu-Fig. 8. Major end points of the SPACE Study. Symbols are: ( ) pla-
cebo; () vitamin E. (Adapted with permission from Boaz et al, Lancet lar mortality demonstrated. Only if and when similar
356:1213–1218, 2000.) results can be demonstrated with antioxidant therapy in
uremia will the true identity of the elephant be fully
recognized.trition, and an acceleration of both the oxidative injury
process and atherosclerosis. Oxidative modification of Reprint requests to Jonathan Himmelfarb, M.D., Division of Ne-
phrology, Maine Medical Center, 22 Bramhall Street, Portland, Maineother substances (for example, 2m) leads to other se-
04102, USA.quelae of uremia.
E-mail: himmej@mmc.org
By advocating for this integrated pathophysiology that
links inflammation, chronic infection, malnutrition, and
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